Yukitaka Kojima

Overview

Yukitaka Kojima is a Principal at E12 Ventures [1][5], where Kojima has worked as an Investor since November 2022 [6]. Kojima is also currently a Principal at Mitsui & Co. Global Investment, Inc., a position held since July 2025 [3], following a prior role as Investor at the same organization from July 2021 to June 2025 [4]. Kojima's investment focus includes healthcare [2], with portfolio exposure spanning companies including Stately Bio, Waypoint Bio, Tacit Tx, Leash Bio, Ensem Tx, Quralis, Bionova (acquired by Servier), and RallyBio (which completed an initial public offering), as well as Ellipsis Health and Rhino FCP [2]. Kojima holds a Bachelor's degree in Economics from The University of Tokyo [11] and serves as a Guest Lecturer at the Institute of Science Tokyo as of April 2025 [7].

Career history

1. M&PrincipalJul 2025 to presentMitsui & Co. Global Investment, Inc.
2. M&InvestorJul 2021 to Jun 2025Mitsui & Co. Global Investment, Inc.
3. PrincipalJul 2025 to presentE12 Ventures
4. InvestorNov 2022 to Jun 2025E12 Ventures
5. IOGuest LecturerApr 2025 to presentInstitute of Science Tokyo (Science Tokyo)
6. M&Investment ManagerSep 2019 to Jun 2021Mitsui & Co., Ltd.
7. M&Commodity SalesJun 2019 to Sep 2019Mitsui & Co., Ltd.
8. M&Interim Head of Precious Metals TradingMar 2017 to Jun 2019Mitsui & Co., Ltd.

Education

1. TUBachelor's degree, Economics2012 - 2016The University of Tokyo